1. Home
  2. GDTC vs MBAI Comparison

GDTC vs MBAI Comparison

Compare GDTC & MBAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CytoMed Therapeutics Limited

GDTC

CytoMed Therapeutics Limited

HOLD

Current Price

$1.00

Market Cap

12.4M

Sector

Health Care

ML Signal

HOLD

Logo Check-Cap Ltd. Ordinary Share

MBAI

Check-Cap Ltd. Ordinary Share

N/A

Current Price

$1.73

Market Cap

12.0M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
GDTC
MBAI
Founded
2018
2004
Country
Singapore
Israel
Employees
N/A
85
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.4M
12.0M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
GDTC
MBAI
Price
$1.00
$1.73
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
7.3K
46.6K
Earning Date
04-24-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$5.37
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.73
$1.31
52 Week High
$3.68
$3.92

Technical Indicators

Market Signals
Indicator
GDTC
MBAI
Relative Strength Index (RSI) 45.73 47.50
Support Level $0.97 $1.38
Resistance Level $1.11 $1.89
Average True Range (ATR) 0.05 0.15
MACD -0.00 0.01
Stochastic Oscillator 32.48 23.94

Price Performance

Historical Comparison
GDTC
MBAI

About GDTC CytoMed Therapeutics Limited

CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.

About MBAI Check-Cap Ltd. Ordinary Share

Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but it currently expects to market products in the United States, Europe, Israel and Japan.

Share on Social Networks: